Halozyme prices USD 1.5 billion 1.5% convertible senior notes due 2033

PUBT · 1d ago
Halozyme prices USD 1.5 billion 1.5% convertible senior notes due 2033
  • Halozyme priced and closed a private placement of USD 1.5 billion 1.5% Convertible Senior Notes due 2033 on Sept. 22, 2026.
  • Net proceeds totaled about USD 1.47 billion, with about USD 187.5 million used to fund capped call transactions.
  • Planned repurchases include about USD 151.7 million of 0.25% convertible senior notes due 2027 for about USD 217 million total cost.
  • Planned repurchases also include USD 220 million of 1% convertible senior notes due 2028 for about USD 435.5 million total cost.
  • Notes carry 1.5% interest, convert at 7.1509 shares per USD 1,000, implying a conversion price of about USD 139.84.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-398015), on September 22, 2026, and is solely responsible for the information contained therein.